Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bedaquiline + rifampicin
- Development stage
- Unknown
- Lead developer
- Janssen Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BE-PEP (Bedaquiline-Enhanced Post-Exposure Prophylaxis) is an investigational combination drug regimen consisting of bedaquiline and rifampicin. Developed by the Institute of Tropical Medicine in Antwerp, Belgium, in collaboration with the Damien Foundation and Janssen Pharmaceuticals, it is designed for the prevention of leprosy in individuals who have been in close contact with leprosy patients. Bedaquiline is a diarylquinoline antibiotic that inhibits mycobacterial ATP synthase, while rifampicin is a rifamycin antibiotic that inhibits bacterial DNA-dependent RNA polymerase. The regimen is currently being evaluated in the Phase 3 BE-PEOPLE trial in the Comoros Islands to determine its efficacy compared to the standard single-dose rifampicin (SDR-PEP) protocol.
- Other names
- Bedaquiline-Enhanced Post-Exposure Prophylaxis
02
Targets
CYP3A4 (Cytochrome P450 3A4)rpoB (DNA-directed RNA polymerase subunit beta)AtpE (Mycobacterium tuberculosis ATP synthase subunit c)
Beyond the preview
Go deeper on bedaquiline + rifampicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bedaquiline + rifampicin.